These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31112623)

  • 1. Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study.
    Chattopadhyay N; Riecke K; Ligges S; Zimmermann T; Halabi A; Schultze-Mosgau MH
    Br J Clin Pharmacol; 2019 Sep; 85(9):2011-2021. PubMed ID: 31112623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment.
    Schultze-Mosgau MH; Lasseter KC; Marbury T; Loewen S; Riecke K
    J Clin Pharmacol; 2020 Aug; 60(8):1030-1038. PubMed ID: 32227643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women.
    Liu H; Jiang J; Chen Z; Zhang Y; Li J; Hoechel J; Rohde B; Zimmermann T; Schultze-Mosgau MH
    Clin Pharmacol Drug Dev; 2021 May; 10(5):486-493. PubMed ID: 32716091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant.
    Dayal S; Aluri J; Hall N; Filippov G; Moline M; Reyderman L; Landry I
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00758. PubMed ID: 33822479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single- and Multiple-Dose Pharmacokinetics and Safety of Vilaprisan in Healthy Postmenopausal Japanese Women: A Randomized Clinical Trial.
    Schultze-Mosgau MH; Matsuki S; Okumura K; Kaneko M
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):49-56. PubMed ID: 34635989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function.
    Yin W; Mitra P; Copalu V; Marbury TC; Rondon JC; Lawitz EJ; Lloyd V; Baratta M; Asgharnejad M; Hui T; Khan Y
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1213. PubMed ID: 38993008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
    Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
    Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
    Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
    Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women
.
    Schultze-Mosgau MH; Schuett B; Hafner FT; Zollmann F; Kaiser A; Hoechel J; Rohde B
    Int J Clin Pharmacol Ther; 2017 Jan; 55(1):16-24. PubMed ID: 27841155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
    Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
    Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
    Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
    Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Food Intake on the Pharmacokinetics of the Selective Progesterone Receptor Modulator Vilaprisan: A Randomized Clinical Study in Healthy Postmenopausal Women.
    Schultze-Mosgau MH; Kaiser A; Zollmann FS
    Clin Pharmacol Drug Dev; 2021 Jun; 10(6):675-680. PubMed ID: 33021044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.
    Kropeit D; McCormick D; Erb-Zohar K; Moiseev VS; Kobalava ZD; Stobernack HP; Zimmermann H; Rübsamen-Schaeff H
    Br J Clin Pharmacol; 2017 Dec; 83(12):2678-2686. PubMed ID: 28722153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
    Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of moderate liver impairment on the pharmacokinetics of opicapone.
    Rocha JF; Santos A; Falcão A; Lopes N; Nunes T; Pinto R; Soares-da-Silva P
    Eur J Clin Pharmacol; 2014 Mar; 70(3):279-86. PubMed ID: 24271646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
    Horsmans Y; Zhou J; Liudmila M; Golor G; Shibolet O; Quinlan M; Emotte C; Boss H; Castro H; Sellami D; Preston RA
    Clin Pharmacokinet; 2018 Mar; 57(3):345-354. PubMed ID: 28577129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment.
    Wang J; Wang X; Zhang ZY; Arora S; Lu S; Kansra V
    J Clin Pharmacol; 2018 May; 58(5):686-693. PubMed ID: 29329482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.
    Peveling-Oberhag J; Zeuzem S; Yong WP; Kunz T; Paquet T; Bouillaud E; Urva S; Anak O; Sellami D; Kobalava Z
    Clin Ther; 2013 Mar; 35(3):215-25. PubMed ID: 23453404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
    Chavan A; Burke L; Sawant R; Navarro-Gonzales P; Vargo D; Paulson SK
    Clin Pharmacol Drug Dev; 2021 Aug; 10(8):950-958. PubMed ID: 33661566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib.
    Magee MH; Shearn S; Shaddinger B; Fang Z; Glaser R
    Br J Clin Pharmacol; 2014 Nov; 78(5):1014-21. PubMed ID: 24938621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.